LOGIN
Edoxaban versus enoxaparin for venous thromboprophylaxis following THA
November 2015
Edoxaban versus enoxaparin for venous thromboprophylaxis following THA
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V
Thromb J. 2015 Aug 12;13:27Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
610 patients in Japan were randomized after total hip arthroplasty (THA) to receive either 30mg/day oral edoxaban, or two injections/day 2000 IU enoxaparin, for 11-14 days. The purpose of the study was to examine the efficacy of edoxaban as a thromboprophylactic drug in comparison to enoxaparin, the current gold standard. The primary outcome was the incidence of venous thromboembolism (VTE), used ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.